ClinicalTrials.gg

Gout clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 347 studies for Gout across more than 10 countries. 50 are recruiting or about to start. 270 of them are mainly about Gout (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Arthritis, Gouty too: 377 studies, 61 open.

Status

Completed
220
Status unknown
35
Recruiting
31
Terminated
17
Not yet recruiting
16
Active, not recruiting
16

Phase

Phase 2
77
Phase 1
64
Phase 3
58
Phase 4
39
Early Phase 1
5

Where

United States
164
China
49
Canada
25
Australia
18
France
18
Germany
16

Who develops what

Add Gout to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 25 programs from 11 companies, 23 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Innovent Biologics, Swedish Orphan Biovitrum and Amgen here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AllopurinolRecent, repeated
Evidence
  • NCT07089875 · Crystalys Therapeutics · Phase 3 · live · comparator · “Allopurinol” · registered Jul 2025
  • NCT06276556 · Atom Therapeutics Co., Ltd · Phase 3 · comparator · “Allopurinol” · registered Feb 2024
  • NCT05818085 · Atom Therapeutics Co., Ltd · Phase 3 · comparator · “Allopurinol” · registered Apr 2023
  • NCT05665699 · InventisBio Co., Ltd · Phase 2 · background · “Allopurinol” · registered Dec 2022
  • NCT05586971 · LG Chem · Phase 3 · comparator · “Allopurinol” · registered Oct 2022
AstraZeneca62% of its industry studiesUS: off-patent, 12 generics marketed45 studies
FebuxostatRecent, repeated
Evidence
  • NCT07498647 · BioRay Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “Febuxostat” · registered Mar 2026
  • NCT07414394 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Febuxostat” · registered Feb 2026
  • NCT06603142 · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd · Phase 3 · live · comparator · “Febuxostat 20MG Tablets” · registered Sep 2024
  • NCT06501534 · Innovent Biologics, Inc. · Phase 2 · comparator · “Febuxostat” · registered Jul 2024
  • NCT05007392 · eisai · Phase 3 · comparator · “Febuxostat” · registered Aug 2021
Takeda51% of its industry studiesUS: off-patent, 12 generics marketedEU: off-patent, 2 generics authorized34 studies
ColchicineRecent, repeated
Evidence
  • NCT07145229 · Atom Therapeutics Co., Ltd · Phase 2 · comparator · “Colchicine” · registered Aug 2025
  • NCT05936281 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2 · comparator · “Colchicine” · registered Jun 2023
  • NCT05936268 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2 · comparator · “Colchicine” · registered Jun 2023
  • NCT04130204 · Dyve Biosciences, Inc. · Phase 2 · background · “Colchicine 0.6 mg” · registered Oct 2019
  • NCT03226899 · Ironwood Pharmaceuticals, Inc. · Phase 4 · background · “colchicine” · registered Jul 2017
Mutual Pharmaceutical Company, Inc.70% of its industry studiesUS: off-patent, 18 generics marketedEU: Agepha Pharma s.r.o. (EMA 2026)23 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tigulixostat☆ Track1 live phase-3 study: NCT07414394Innovent Biologics, Inc.
dotinurad☆ Track1 live phase-3 study: NCT07089875Crystalys Therapeutics
PegloticaseApproved: US 2010☆ Track1 live phase-3 study: NCT07388498Amgen

The 3 in phase 3 with the nearest primary completion, of 25 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.AR882, XOI Low Dose · Swedish Orphan Biovitrum · Phase 2 named, not the main aimNCT07116746 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients — primary endpoint: Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6 · 15 enrolled
  • 30 Apr 2027 est.tigulixostat · Innovent Biologics, Inc. · Phase 3 main aimvs FebuxostatNCT07414394 Tigulixostat (IBI128) vs Febuxostat in Gout — primary endpoint: Proportion of Participants Achieving Serum Uric Acid <360 μmol/L at Week 24 · 600 enrolled
  • Jul 2027 est.dotinurad · Crystalys Therapeutics · Phase 2 main aimNCT07535034 A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants — primary endpoint: Percentage of Participants With an sUA Level <6.0 mg/dL at Week 24 · 90 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Gout studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 1 open

Coming up

21studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 31
AgeWomenMen
100 (0%)0 (0%)
1827 (87%)27 (87%)
3030 (97%)30 (97%)
4031 (100%)31 (100%)
5031 (100%)31 (100%)
6530 (97%)30 (97%)
7524 (77%)24 (77%)
8518 (58%)18 (58%)

Across all 347 studies, recruiting or not: 40% stop at 75 or younger and 20% at 65; 5% take children; <1% are for women only and 7% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Gout studies take

Of 41 phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo2–14 · 41 studies6 mo1–14 · 37 studies—
Phase 214 mo7–22 · 30 studies14 mo7–19 · 25 studies—
Phase 320 mo17–25 · 21 studies——
Phase 421 mo17–39 · 19 studies——
Interventional, no phase29 mo11–43 · 35 studies—29 mo11–43 · 34 studies
Observational67 mo20–122 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 347. Browse all 347 → or search them.